source
- BioMarin halts development of BMN 401 after phase 3 missBioMarin Pharmaceutical announced it is ending all work on its experimental enzyme replacement therapy BMN 401 following a late‑stage trial that did not meet one of two primary goals in patients wi…
- Senate introduces BINSA bill to tighten review of China biotech and pharma transactionsThe U.S. Senate has introduced the Biotech Innovation and National Security Act (BINSA), a bill that would tighten oversight of biotech and pharmaceutical transactions involving China. The proposa…